Ono Pharmaceutical (4528.T)

Executive Summary

Ono Pharmaceutical is a Japan-based biopharmaceutical company with a strong focus on oncology, immunology, and neurology. With a pipeline of 187 drug candidates, the company leverages strategic partnerships—most notably with Bristol-Myers Squibb for nivolumab (Opdivo)—to drive innovation and global commercialization. Ono's commercial portfolio includes 17 marketed products, and its R&D efforts target high-unmet-need areas such as primary CNS lymphoma and multiple system atrophy. The company's solid financial position and deep pipeline support a positive long-term outlook, though near-term growth depends on successful data readouts and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for ONO-2808 in Multiple System Atrophy60% success
• Q4 2026Regulatory decision on nivolumab combination therapy for gastric cancer in Japan70% success
• Q1 2027Interim efficacy update from Phase 2 trial of tirabrutinib in Primary CNS Lymphoma50% success